Haploidentical Hematopoietic Stem Cell Transplantation

Thalassemia Clinical Trial

Official title:

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE AND THALASSEMIA USING CD34+ POSITIVE SELECTED GRAFTS

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02165007
• Other study ID #: HAPSICKLE
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: January 2015
• Est. completion date: March 2026

Study information

• Verified date: September 2023
• Source: Children's National Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is designed as a Pilot/Phase 1 trial of reduced intensity Haploidentical HSCT in patients with sickle cell disease and thalassemia. The purpose of the study is to assess the safety and toxicity of reduced intensity conditioning haploidentical hematopoietic stem cell transplantation.

Description:

Research subjects will undergo reduced intensity conditioning (Hydroxyurea, ATG, Fludarabine, Thiotepa, Melphalan) followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year

The use of the CliniMACS device for CD34 selection will be performed at CNMC through cross-reference of the master file for CliniMACS CD34+ Reagent by Milteyni Biotech (BB-MF 8061).

CliniMACs is an electromechanical device intended to isolate certain cell subsets from mixed cell populations. When used in combination with the CliniMACs CD34 reagent, it is possible to prepare extremely pure populations of CD34+ cells with upwards of 5 logs depletion of contaminating T cells within a closed and sterile system.

We intend to use this system to select cells from HLA haploidentical related donors who have been mobilized with G-CSF prior to stem cell collection. Since previous investigations of this strategy in adult patients have not translated into enhanced long term survival, we intend to limit this protocol to patients under the age of 22 as they have more rapid immune reconstitution.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 27
• Est. completion date: March 2026
• Est. primary completion date: July 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 22 Years

Eligibility

Inclusion Criteria:

• First allogeneic transplant

• Age up to 22 years

• Patients with severe sickle cell disease (stroke, elevated TCD velocities, >2 acute chest syndrome, ongoing chronic red cell transfusion > 6 months)

• Patients with transfusion dependent thalassemia and evidence of iron overload

• Patients must have a related donor that is HLA-matched at >/=4 of 8 but <8/8 HLA-A, -B, -C and -DRB1

• Cardiac function: Shortening fraction >25%; ejection fraction >40%

• Estimated creatinine clearance greater than 50 mL/minute

• Pulmonary function: DLCO =40% (adjusted for hemoglobin) and FEV1=50% in patients 7 years and older with normal cognitive function and able to perform the test adequately. If not able to complete the testing a CT chest will be required., oxygen saturation>91%

• Liver function: direct (conjugated) bilirubin < 2x the upper limit of normal and ALT/AST < 2.5x the upper normal limit.

• Signed informed consent.

Exclusion Criteria:

• Life expectancy less than 6 months

• Patients with uncontrolled bacterial, viral or fungal infections (undergoing appropriate treatment and with progression of clinical symptoms) within 1 month prior to conditioning. Patients with febrile illness or suspected minor infection should await clinical resolution prior to starting conditioning.

• Pregnant or breastfeeding patients

• Patients seropositive for the human immunodeficiency virus (HIV)

• Patient with active Hepatitis B or C determined by serology and/or NAAT

• Active hepatitis, bridging fibrosis or cirrhosis on liver biopsy (biopsy required for patients on chronic transfusion therapy for > 1 year and evidence of iron overload with ferritin >1000 ng/mL)

• Patients with suitable 8/8 HLA matched related and unrelated donors

• Patients who have an intolerance to or have received alemtuzumab in the prior 6 months will be excluded from enrollment unless alemtuzumab is replaced with rabbit ATG in the conditioning regimen

Related Conditions & MeSH terms

• Sickle Cell-thalassemia Disease
• Thalassemia

Intervention

Drug:
• peripheral blood stem cell graft that are CD34+ selected
The preparatory regimen will consist of Hydroxyurea from Days -50 to -22, Alemtuzumab from days -21 to -19 (test dose Alemtuzumab on day -22), Fludarabine days -8 to -4, Thiotepa Day -4, Melphalan day -3 to -2 (Table 4a). In patients with intolerance to or have received alemtuzumab in the prior 6 months, alemtuzumab will be replaced with rabbit ATG on days -10 through -7, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year.

Locations

Country	Name	City	State
United States	Childrens National Medical Center	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
Catherine Bollard	Children's National Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Graft failure	Graft failure upto 2 years	2 years
Other	Grades II-IV and III-IV acute GVHD	Grades II-IV and III-IV acute GVHD at day +180	180 days
Other	Chronic GVHD	Chronic GVHD by 1 yea	1 year
Other	Transplant-related mortality	Transplant-related mortality at Day+ 100	100 days
Other	Viral infection rates	Viral infection rates at 6 months: Reactivation of CMV, Adenovirus and EBV detected on peripheral blood monitoring or any visceral disease with documented molecular studies for these viruses within the first six months post transplantation will be recorded	6 months
Other	Lymphocyte reconstitution	Lymphocyte reconstitution upto 1 year post transplant	1 year
Primary	Incidence of transplant related adverse outcomes	The primary endpoint of this trial is safety. Transplant related adverse outcomes and non-hematological toxicity will be measured through Day +60 on this objective to include: Non-hematological severe (Grade IV and V) organ specific toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0); Rates of non-engraftment; Severe acute (Grade III-IV); Veno-occlusive disease of the liver; Idiopathic pneumonia syndrome; Seizures/Posterior reversible encephalopathy syndrome (PRES)	60 days
Secondary	Overall survival	Overall survival upto 2 years	2 years